Lupus Nephritis Market

Key Highlights:

 

  • In 2021, the total Low-grade glioma market size was USD 1577.8 Million which is expected to rise during the study period (2019–2032)
  • The total diagnosed cases of Lupus Nephritis was 209,166 cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032
  • Low-grade glioma companies working in the market are - Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, and others

 

Request a sample to unlock the CAGR for  Lupus Nephritis Market

 

DelveInsight's "Lupus Nephritis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lupus Nephritis, historical and forecasted epidemiology as well as the Lupus Nephritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Lupus Nephritis market report provides current treatment practices, emerging drugs, Lupus Nephritis market share of the individual therapies, current and forecasted Lupus Nephritis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Lupus Nephritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Geography Covered

 

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

 

Study Period: 2019-2032

 

Lupus Nephritis Understanding and Treatment Algorithm

 

The DelveInsight’s Lupus Nephritis market insights report gives a thorough understanding of Lupus Nephritis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Systemic lupus erythematosus (Systemic lupus erythematosus) is an autoimmune disease that results in chronic inflammation and damage of more than one organ. It is diagnosed clinically and serologically with the presence of autoantibodies. One common and severe manifestation that should be looked for in Systemic lupus erythematosus is the involvement of the kidneys, known as lupus nephritis (LN). Evaluating kidney function in patients suffering from Systemic lupus erythematosus is vital as timely detection and management of renal impairment can greatly improve renal outcomes. Lupus Nephritis typically occurs 3 years after and usually within 5 years of the onset of Systemic lupus erythematosus. Histological evidence of Lupus Nephritis is present in most Systemic lupus erythematosus patients, even those who do not clinically manifest renal disease.

 

It can cause many signs and symptoms and may be different for everyone. Signs of lupus nephritis include blood in the urine (hematuria): Glomerular disease can cause the glomeruli to leak blood into the urine. And the urine may look pink or light brown from blood, but most often, they will not be able to see the blood cells except with a microscope. And the protein in the urine (proteinuria): Glomerular disease can cause the glomeruli to leak protein into the urine. The urine may be foamy because of the protein. Edema: Having extra fluid that the kidneys cannot remove that causes swelling in body parts like legs, ankles, or around eyes, etc. And Weight gain due to the fluid in the body cannot get rid of high blood pressure.

 

Lupus Nephritis Diagnosis

 

Lupus Nephritis is diagnosed through urine and blood tests and a kidney biopsy. One of the first signs of Lupus Nephritis is blood in the urine or extremely foamy urine. High blood pressure and swelling in the feet also might indicate lupus nephritis. The blood test measures creatinine, a waste product from the normal breakdown of muscles in the body that is removed from the blood by kidneys.

 

Lupus Nephritis Epidemiology 

The epidemiology section provides insights about the historical and current Lupus Nephritis patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
 

Key Findings

 

The disease epidemiology covered in the report provides historical as well as forecasted Lupus Nephritis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

 

In the year 2021, the total diagnosed cases of Lupus Nephritis was 209,166 cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032.

 

Lupus Nephritis Epidemiology

 

The disease epidemiology covered in the report provides historical as well as forecasted Lupus Nephritis epidemiology [segmented as Total Prevalent Cases of Lupus Nephritis, Total Diagnosed Cases of Lupus Nephritis, Total Treated Cases of Lupus Nephritis] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

 

Country Wise- Lupus Nephritis Epidemiology

 

The epidemiology segment also provides the Lupus Nephritis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

Lupus Nephritis Drug Chapters

The drug chapter segment of the Lupus Nephritis report encloses the detailed analysis of Lupus Nephritis marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Lupus Nephritis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Lupus Nephritis Emerging Drugs

 

The report provides the details of the emerging therapies under the late and mid-stage of development for Lupus Nephritis treatment.

 

Lupus Nephritis Market

 

Lupus Nephritis Market Outlook

The Lupus Nephritis market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Lupus Nephritis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand of better technology.

 

This segment gives a thorough detail of Lupus Nephritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Lupus Nephritis market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Key Findings

 

The Lupus Nephritis market size in the 7MM is expected to change during the study period 2019–2032. The therapeutic market of Lupus Nephritis in the seven major markets is expected to increase during the study period (2019–2032). In 2021, the total Lupus Nephritis market size was USD 1,577.8 million which is expected to rise during the study period (2019–2032). 

 

The United States Market Outlook

 

The total Lupus Nephritis market size in the United States accounted for USD 975.1 million in 2021 which is expected to rise during the study period (2019–2032).

 

EU-5 Countries: Market Outlook

 

In EU5, the total Lupus Nephritis market size was USD 392 million in 2021, which is expected to rise during the study period (2019–2032).

 

Japan Market Outlook

 

In Japan, the total Lupus Nephritis market size was USD 211.1 million in 2021, which is expected to rise during the study period (2019–2032).

 

Lupus Nephritis Market Share3

 

Lupus Nephritis Drug Uptake

 

This section focuses on the rate of uptake of the potential drugs recently launched in the Lupus Nephritis market or expected to get launched in the market during the study period 2019-2032. The analysis covers Lupus Nephritis market uptake by drugs; patient uptake by therapies; and sales of each drug.   

 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

 

Lupus Nephritis Pipeline Development Activities

 

The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Lupus Nephritis's key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

 

The report covers the detailed information of collaborations, acquisition, and merger, licensing patent details, and other information for Lupus Nephritis emerging therapies.

 

Reimbursement Scenario in Lupus Nephritis

 

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

KOL- Views

 

To keep up with current Lupus Nephritis market trends, we take KOLs and SMEs ' opinions working in the Lupus Nephritis domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Lupus Nephritis market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

 

Competitive Intelligence Analysis

 

We perform Competitively and Market Intelligence analysis of the Lupus Nephritis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

Market Size

USD 1577.8 Million in 2021

Key Companies

DAurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, and others

Scope of the Lupus Nephritis Market Report

 

  • The report covers the descriptive overview of Lupus Nephritis, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
  • Comprehensive insight has been provided into the Lupus Nephritis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Lupus Nephritis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Lupus Nephritis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Lupus Nephritis market

 

Lupus Nephritis Report Highlights

 

  • In the coming years, the Lupus Nephritis market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Lupus Nephritis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
  • Major players are involved in developing therapies for Lupus Nephritis. The launch of emerging therapies will significantly impact the Lupus Nephritis market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Lupus Nephritis
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Lupus Nephritis Report Insights

 

  • Patient Population
  • Therapeutic Approaches
  • Lupus Nephritis Pipeline Analysis
  • Lupus Nephritis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

 

Lupus Nephritis Report Key Strengths

 

  • 11 Years Forecast
  • 7MM Coverage
  • Lupus Nephritis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Lupus Nephritis Drugs Uptake

 

Lupus Nephritis Report Assessment

 

  • Current Treatment Practices
  • Lupus Nephritis Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Lupus Nephritis Market Drivers 
  • Lupus Nephritis Market Barriers

 

Key Questions Answered In The Lupus Nephritis Market Report

 

Lupus Nephritis Market Insights:

 

  • What was the Lupus Nephritis drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Lupus Nephritis total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings of the market across 7MM and which country will have the largest Lupus Nephritis market size during the forecast period (2019-2032)?
  • At what CAGR, the Lupus Nephritis market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the Lupus Nephritis market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Lupus Nephritis market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

 

Lupus Nephritis Epidemiology Insights:

 

  • What are the disease risk, burden, and regional/ethnic differences of Lupus Nephritis?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical Lupus Nephritis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Lupus Nephritis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM concerning the patient population about Lupus Nephritis?
  • Out of all 7MM countries, which country would have the highest prevalent population of Lupus Nephritis during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

 

  • What are the current options for the Lupus Nephritis treatment in addition to the approved therapies?
  • What are the current treatment guidelines for the treatment of Lupus Nephritis in the USA, Europe, and Japan?
  • What are the Lupus Nephritis marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of Lupus Nephritis?
  • How many therapies are in-development by each company for Lupus Nephritis treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Lupus Nephritis treatment?
  • What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Lupus Nephritis therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Lupus Nephritis and its status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for Lupus Nephritis?
  • What are the global historical and forecasted markets of Lupus Nephritis?

 

What Should You Buy Lupus Nephritis Market Report?

 

  • The report will help in developing business strategies by understanding trends shaping and driving the Lupus Nephritis market
  • To understand the future market competition in the Lupus Nephritis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Lupus Nephritis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the Lupus Nephritis market
  • To understand the future market competition in the Lupus Nephritis market

Frequently Asked Questions

What is Lupus Nephritis?
When lupus autoantibodies damage the kidney structures that filter waste, lupus nephritis develops. This results in inflammation of the kidneys, which can cause blood or protein to pass through the urine, high blood pressure, decreased kidney function, or even renal failure.
What is the Lupus Nephritis Market Size in 7MM?
The total Lupus Nephritis market size was accounted for USD 1,577.8 Million in the year 2021 and is estimated to grow during the study period (2019-2032).
Who are the leading companies in the Lupus Nephritis Market Landscape?
The key players in the Lupus Nephritis market who are in different phases of developing Lupus Nephritis Therapies are - Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, and others.
What are the Key strengths of the Lupus Nephritis Market Report?
Key strengths of the Lupus Nephritis Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers, and Market Barriers, along with the upcoming market trends in the Lupus Nephritis Market.
Which country is expected to account for the most significant prevalent cases for Lupus Nephritis in the 7MM?
The United States is expected to account for the highest prevalent Lupus Nephritis cases.

1. Key Insights

2. Executive Summary

3. Lupus Nephritis: Market Overview at a Glance

3.1. Total Market Share (%) Distribution of Lupus Nephritis in 2019

3.2. Total Market Share (%) Distribution of Lupus Nephritis in 2032

4. Lupus Nephritis: Disease Background and Overview

4.1. Introduction

4.2. Causes

4.3. Risk Factors

4.4. Symptoms

4.5. Other Clinical Manifestation

4.6. Prognosis of lupus nephritis

4.7. Clinical presentation of lupus nephritis

4.8. Pathogenesis

4.9. Classification

4.9.1. LN World Health Organization 1964 Classification

4.9.2. LN World Health Organization 1964 Classification

4.9.3. World Health Organization (WHO) morphologic classification of lupus nephritis (modified in 1982)

4.9.4. LN World Health Organization 1964 Classification

4.9.5. International Society of Nephrology (ISN) and Renal Pathology Society (RPS) 2003 Classification for LN

4.9.6. LN World Health Organization 1964 Classification

4.10. Diagnosis

5. Epidemiology and Patient Population

5.1. Key Findings

6. 7MM Total Prevalent Patient Population of LN

7. Country Wise-Epidemiology of Lupus Nephritis

7.1. United States

7.1.1. Assumptions and Rationale

7.1.2. Total Prevalent Population of Lupus Nephritis

7.1.3. Total Diagnosed Population of Lupus Nephritis

7.1.4. Gender-Specific Prevalent Population of Lupus Nephritis

7.1.5. Class- Specific cases of Lupus Nephritis

7.1.6. Clinical Manifestations of Lupus Nephritis

7.2. EU5 Countries

7.2.1. Assumptions and Rationale

7.3. Germany

7.3.1. Total Prevalent Population of Lupus Nephritis

7.3.2. Total Diagnosed Population of Lupus Nephritis

7.3.3. Gender-Specific Prevalent Population of Lupus Nephritis

7.3.4. Class- Specific cases of Lupus Nephritis

7.3.5. Clinical Manifestations of Lupus Nephritis

7.4. France

7.4.1. Total Prevalent Population of Lupus Nephritis

7.4.2. Total Diagnosed Population of Lupus Nephritis

7.4.3. Gender-Specific Prevalent Population of Lupus Nephritis

7.4.4. Class- Specific cases of Lupus Nephritis

7.4.5. Clinical Manifestations of Lupus Nephritis

7.5. Italy

7.5.1. Total Prevalent Population of Lupus Nephritis

7.5.2. Total Diagnosed Population of Lupus Nephritis

7.5.3. Gender-Specific Prevalent Population of Lupus Nephritis

7.5.4. Class- Specific cases of Lupus Nephritis

7.5.5. Clinical Manifestations of Lupus Nephritis

7.6. United Kingdom

7.6.1. Total Prevalent Population of Lupus Nephritis

7.6.2. Total Diagnosed Population of Lupus Nephritis

7.6.3. Gender-Specific Prevalent Population of Lupus Nephritis

7.6.4. Class- Specific cases of Lupus Nephritis

7.6.5. Clinical Manifestations of Lupus Nephritis

7.7. Spain

7.7.1. Total Prevalent Population of Lupus Nephrites

7.7.2. Total Diagnosed Population of Lupus Nephritis

7.7.3. Gender-Specific Prevalent Population of Lupus Nephritis

7.7.4. Class- Specific cases of Lupus Nephritis

7.7.5. Clinical Manifestations of Lupus Nephritis

7.8. Japan

7.8.1. Assumptions and Rationale

7.8.2. Total Prevalent Population of Lupus Nephrites

7.8.3. Total Diagnosed Population of Lupus Nephritis

7.8.4. Gender-Specific Prevalent Population of Lupus Nephritis

7.8.5. Class- Specific cases of Lupus Nephritis

7.8.6. Clinical Manifestations of Lupus Nephritis

8. Treatment

8.1. Treatment Goals

8.2. Medications

8.3. General Treatment

8.4. Treatment Guidelines

8.4.1. American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis

8.4.2. EULAR Guidelines for the treatment of Lupus Nephritis

8.4.3. KDIGO Guidelines For the treatment of Lupus Nephritis

9. Unmet Needs

10. Patient Journey

11. Case Studies

12. Marketed Therapies

12.1. LUPKYNISTM: Aurinia Pharmaceuticals

12.1.1. Drug Description

12.1.2. Regulatory Milestones

12.1.3. Other Development Activities

12.1.4. Safety and Efficacy

12.1.5. Product Profile

To be continued in the report….

13. Key Cross Competitors

14. Emerging Therapies

14.1. Obinutuzumab: Roche

14.1.1. Product Description

14.1.2. Other development Activities

14.1.3. Clinical Development

14.1.4. Safety and Efficacy

14.1.5. Product Profile

14.2. Anifrolumab: AstraZeneca

14.2.1. Product Description

14.2.2. Other Development Activities

14.2.3. Clinical Development

14.2.4. Safety and Efficacy

14.2.5. Product Profile

To be continued in the report….

15. Other Promising Candidates

15.1. BI 655064: Boehringer Ingelheim

15.1.1. Product Description

15.1.2. Clinical Development

15.1.3. Safety and Efficacy

15.1.4. Product Profile

15.2. Iscalimab: Novartis

15.2.1. Product Description

15.2.2. Product Development Activities

15.2.3. Clinical Development

15.2.4. Product Profile

16. Lupus Nephritis: 7 Major Market Analysis

16.1. Key Findings

16.2. Market Size of Lupus Nephritis in 7MM

16.3. Market Size of Lupus Nephritis by Therapies in First Line Patients in 7MM

16.4. Market Size of Lupus Nephritis by Therapies in Second Line Patients in 7MM

17. United States Market Outlook

17.1. United States Market Size

17.1.1. Total Market size of LN

17.1.2. Market Size of Lupus Nephritis by Therapies in First Line Patients in the US

17.1.3. Market Size of Lupus Nephritis by Therapies of Second Line Patients in The US

18. EU-5 Countries: Market Outlook

18.1. Germany

18.1.1. Total Market size of LN

18.1.2. Market Size of LN by Therapies in First Line Patients in Germany

18.1.3. Market Size of LN by Therapies of Second Line Patients in Germany

18.2. France

18.2.1. Total Market size of LN

18.2.2. Market Size of LN by Therapies in First Line Patients in France

18.2.3. Market Size of LN by Therapies of Second Line Patients in France

18.3. Italy

18.3.1. Total Market size of LN

18.3.2. Market Size of LN by Therapies in First Line Patients in Italy

18.3.3. Market Size of LN by Therapies of Second Line Patients in Italy

18.4. United Kingdom

18.4.1. Total Market size of LN

18.4.2. Market Size of LN by Therapies in First Line Patients in the UK

18.4.3. Market Size of LN by Therapies of Second Line Patients in the UK

18.5. Spain

18.5.1. Total Market size of LN

18.5.2. Market Size of LN by Therapies in First Line Patients in Spain

18.5.3. Market Size of LN by Therapies of Second Line Patients in Spain

19. Japan: Market Outlook

19.1. Japan Market Size

19.2. Total Market size of LN

19.3. Market Size of LN by Therapies in First Line Patients in Japan

19.4. Market Size of LN by Therapies of Second Line Patients in Japan

20. Market Drivers

21. Market Barriers

22. SWOT Analysis

23. Market Access and Reimbursement

24. Appendix

24.1. Report Methodology

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

List of Table

Table 1: Summary of Lupus Nephritis Market, Epidemiology and Key Events (2019-2032)

Table 2: Total Prevalent Population of LN in the 7MM (2019-2032)

Table 3: Total Prevalent Population of LN in the US (2019-2032)

Table 4: Diagnosed Cases of LN in the US (2019-2032)

Table 5: Gender Specific Prevalence of LN in the US (2019-2032)

Table 6: Class specific cases of LN in the US (2019-2032)

Table 7: Clinical Manifestations of LN in the US (2019-2032)

Table 8: Total Prevalent Population of LN in Germany (2019-2032)

Table 9: Diagnosed Cases of LN in Germany (2019-2032)

Table 10: Gender Specific Prevalence of LN in Germany (2019-2032)

Table 11: Class specific cases of LN in Germany (2019-2032)

Table 12: Clinical Manifestations of LN in Germany (2019-2032)

Table 13: Total Prevalent Population of LN in France (2019-2032)

Table 14: Diagnosed Cases of LN in France (2019-2032)

Table 15: Gender Specific Prevalence of LN in France (2019-2032)

Table 16: Class specific cases of LN in France (2019-2032)

Table 17: Clinical Manifestations of LN in France (2019-2032)

Table 18: Total Prevalent Population of LN in Italy (2019-2032)

Table 19: Diagnosed Cases of LN in Italy (2019-2032)

Table 20: Gender Specific Prevalence of LN in Italy (2019-2032)

Table 21: Class specific cases of LN in Italy (2019-2032)

Table 22: Clinical Manifestations of LN in Italy (2019-2032)

Table 23: Total Prevalent Population of LN in the United Kingdom (2019-2032)

Table 24: Diagnosed Cases of LN in the United Kingdom (2019-2032)

Table 25: Gender Specific Prevalence of LN in the United Kingdom (2019-2032)

Table 26: Class specific cases of LN in the United Kingdom (2019-2032)

Table 27: Clinical Manifestations of LN in the United Kingdom (2019-2032)

Table 28: Total Prevalent Population of LN in Spain (2019-2032)

Table 29: Diagnosed Cases of LN in Spain (2019-2032)

Table 30: Gender Specific Prevalence of LN in Spain (2019-2032)

Table 31: Class specific cases of LN in Spain (2019-2032)

Table 32: Clinical Manifestations of LN in Spain (2019-2032)

Table 33: Total Prevalent Population of LN in Japan (2019-2032)

Table 34: Diagnosed Cases of LN in Japan (2019-2032)

Table 35: Gender Specific Prevalence of LN in Japan (2019-2032)

Table 36: Class specific cases of LN in Japan (2019-2032)

Table 37: Clinical Manifestations of LN in Japan (2019-2032)

Table 38: Guidelines compared; common views and differences

Table 39: Key Cross Emerging Therapies

Table 40: Obinutuzumab, Clinical Trial Description, 2021

Table 41: Anifrolumab, Clinical Trial Description, 2021

Table 42: BI 655064, Clinical Trial Description, 2021

Table 43: Iscalimab, Clinical Trial Description, 2021

Table 44: 7 Major Market Size of LN in USD Million (2019-2032)

Table 45: 7 Major Market Size by Therapies for First Line Patients of LN in USD Million (2019-2032)

Table 46: 7 Major Market Size by Therapies for Second Line Patients of LN in USD Million (2019-2032)

Table 47: Market Size of LN in the US, USD Million (2019-2032)

Table 48: USA Market Size by Therapies for First Line Patients of LN in USD Million (2019-2032)

Table 49: Market Size by Therapies for Second Line Patients of LN in the US, in USD Million (2019-2032)

Table 50: Market Size of LN in Germany, USD Million (2019-2032)

Table 51: Germany Market Size by Therapies for First Line Patients of LN in USD Million (2019-2032)

Table 52: Market Size by Therapies for Second Line Patients of LN in Germany, USD Million (2019-2032)

Table 53: Market Size of LN in France, USD Million (2019-2032)

Table 54: France Market Size by Therapies for First Line Patients of LN in USD Million (2019-2032)

Table 55: Market Size by Therapies for Second Line Patients of LN in France, USD Million (2019-2032)

Table 56: Market Size of LN in Italy, USD Million (2019-2032)

Table 57: Italy Market Size by Therapies for First Line Patients of LN in USD Million (2019-2032)

Table 58: Market Size by Therapies for Second Line Patients of LN in Italy, USD Million (2019-2032)

Table 59: Market Size of LN in the UK, USD Million (2019-2032)

Table 60: UK Market Size by Therapies for First Line Patients of LN in USD Million (2019-2032)

Table 61: Market Size by Therapies for Second Line Patients of LN in the UK, USD Million (2019-2032)

Table 62: Market Size of LN in Spain, USD Million (2019-2032)

Table 63: Spain Market Size by Therapies for First Line Patients of LN in USD Million (2019-2032)

Table 64: Market Size by Therapies for Second Line Patients of LN in Spain, USD Million (2019-2032)

Table 65: Market Size of LN in Japan, USD Million (2019-2032)

Table 66: Japan Market Size by Therapies for First Line Patients of LN in USD Million (2019-2032)

Table 67: Market Size by Therapies for Second Line Patients of LN in Japan, USD Million (2019-2032)

List of Figures

Figure 1: Summary of Lupus Nephritis Market, Epidemiology and Key Events (2019-2032)

Figure 2: Clinical Manifestations of SLE and Lupus Nephritis

Figure 3: Risk Factors of Lupus Nephritis

Figure 4: Symptoms associated with Lupus Nephritis

Figure 5: Symptoms associated with Lupus Nephritis

Figure 6: Lupus Nephritis Pathogenesis

Figure 7: Therapeutic targets for LN

Figure 8: Pathomechanisms of LN outside the kidney

Figure 9: Therapeutic targets for LN

Figure 10: Total Prevalent Patient Population of LN in the 7MM (2019-2032)

Figure 11: Total Prevalent Population of LN in the US (2019-2032)

Figure 12: Diagnosed Cases of LN in the US (2019-2032)

Figure 13: Gender Specific Prevalence of LN in the US (2019-2032)

Figure 14: Class specific cases of LN in the US (2019-2032)

Figure 15: Clinical Manifestations of LN in the US (2019-2032)

Figure 16: Total Prevalent Population of LN in Germany (2019-2032)

Figure 17: Diagnosed Cases of LN in Germany (2019-2032)

Figure 18: Gender Specific Prevalence of LN in Germany (2019-2032)

Figure 19: Class specific cases of LN in Germany (2019-2032)

Figure 20: Clinical Manifestations of LN in Germany (2019-2032)

Figure 21: Total Prevalent Population of LN in France (2019-2032)

Figure 22: Diagnosed Cases of LN in France (2019-2032)

Figure 23: Gender Specific Prevalence of LN in France (2019-2032)

Figure 24: Class specific cases of LN in France (2019-2032)

Figure 25: Clinical Manifestations of LN in France (2019-2032)

Figure 26: Total Prevalent Population of LN in Italy (2019-2032)

Figure 27: Diagnosed Cases of LN in Italy (2019-2032)

Figure 28: Gender Specific Prevalence of LN in Italy (2019-2032)

Figure 29: Class specific cases of LN in Italy (2019-2032)

Figure 30: Clinical Manifestations of LN in Italy (2019-2032)

Figure 31: Total Prevalent Population of LN in the United Kingdom (2019-2032)

Figure 32: Diagnosed Cases of LN in the United Kingdom (2019-2032)

Figure 33: Gender Specific Prevalence of LN in the United Kingdom (2019-2032)

Figure 34: Class specific cases of LN in The United Kingdom (2019-2032)

Figure 35: Clinical Manifestations of LN in the United Kingdom (2019-2032)

Figure 36: Total Prevalent Population of LN in Spain (2019-2032)

Figure 37: Diagnosed Cases of LN in Spain (2019-2032)

Figure 38: Gender Specific Prevalence of LN in Spain (2019-2032)

Figure 39: Class specific cases of LN in Spain (2019-2032)

Figure 40: Clinical Manifestations of LN in Spain (2019-2032)

Figure 41: Total Prevalent Population of LN in Japan (2019-2032)

Figure 42: Diagnosed Cases of LN in Japan (2019-2032)

Figure 43: Gender Specific Prevalence of LN in Japan (2019-2032)

Figure 44: Class specific cases of LN in Japan (2019-2032)

Figure 45: Clinical Manifestations of LN in Japan (2019-2032)

Figure 46: Treatment approach for patients with lupus nephritis

Figure 47: Treatment approach for Refractory lupus nephritis

Figure 48: Therapeutic targets for LN

Figure 49: Therapeutic targets for LN

Figure 50: Unmet Needs of Lupus Nephritis

Figure 51: 7 Major Market Size of LN in USD Million (2019-2032)

Figure 52: 7 Major Market Size by Therapies for First Line Patients of LN in USD Million (2019-2032)

Figure 53: 7 Major Market Size by Therapies for Second Line Patients of LN in USD Million (2019-2032)

Figure 54: Mean adjusted total costs, total and by type of service

Figure 55: Average annual cost of illness per patient by condition

Figure 56: Market Size of LN in the US, USD Million (2019-2032)

Figure 57: Market Size of First Line Patients by Therapies for LN in the US, USD Million (2019-2032)

Figure 58: Market Size by Therapies for Second line Patients of LN in The US, USD Million (2019-2032)

Figure 59: Market Size of LN in Germany, USD Million (2019-2032)

Figure 60: Market Size of First Line Patients by Therapies for LN in Germany, USD Million (2019-2032)

Figure 61: Market Size by Therapies for Second line Patients of LN in Germany, USD Million (2019-2032)

Figure 62: Market Size of LN in France, USD Million (2019-2032)

Figure 63: Market Size of First Line Patients by Therapies for LN in France, USD Million (2019-2032)

Figure 64: Market Size by Therapies for Second line Patients of LN in France, USD Million (2019-2032)

Figure 65: Market Size of LN in Italy, USD Million (2019-2032)

Figure 66: Market Size of First Line Patients by Therapies for LN in Italy, USD Million (2019-2032)

Figure 67: Market Size by Therapies for Second line Patients of LN in Italy, USD Million (2019-2032)

Figure 68: Market Size of LN in the UK, USD Million (2019-2032)

Figure 69: Market Size of First Line Patients by Therapies for LN in the UK, USD Million (2019-2032)

Figure 70: Market Size by Therapies for Second line Patients of LN in The UK, USD Million (2019-2032)

Figure 71: Market Size of LN in Spain, USD Million (2019-2032)

Figure 72: Market Size of First Line Patients by Therapies for LN in Spain, USD Million (2019-2032)

Figure 73: Market Size by Therapies for Second line Patients of LN in Spain, USD Million (2019-2032)

Figure 74: Market Size of LN in Japan, USD Million (2019-2032)

Figure 75: Market Size of First Line Patients by Therapies for LN in Japan, USD Million (2019-2032)

Figure 76: Market Size by Therapies for Second line Patients of LN in Japan, USD Million (2019-2032)

Figure 77: Market Drivers

Figure 78: Market Barriers

Aurinia Pharmaceuticals
Roche
AstraZeneca
Boehringer Ingelheim
Novartis

 

Forward to Friend

Need A Quote